Skip to content
OpenCapital
Get started

Idexx Laboratories IDXX Cash & Equivalents

Cash & Equivalents at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$3.28B-21.4%
Neogen logo
NeogenNEOG
$159.9M+25.2%
Danaher logo
DanaherDHR
$5.7B+186%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$509M-2.7%
Agilent Technologies logo
Agilent TechnologiesA
$1.81B+21.5%
Quest Diagnostics logo
Quest DiagnosticsDGX
$393M+109%

Other financials

Income statement

See full
Revenue$1.1B+14.3%
Gross profit$722.7M+15.9%
Operating income$362.6M+14.5%
Net income$278.4M+14.7%
EPS (diluted)$3.47+17.2%

Balance sheet

See full
Total debt$575.5M-22.2%
Total equity$1.6B+7.5%
Total assets$3.4B+5.3%

Cash flow

See full
Operating cash flow$266.2M+11.9%
CapEx$32.0M+6.5%
Free cash flow$234.3M+12.7%

Valuation

See full
Market cap$43.78B+3.9%
Enterprise value$44.15B+3.4%
P/E40×-7.1×
P/S9.9×-0.9×

Profitability

See full
Gross margin62.1%+0.8pp
Operating margin31.6%+2.5pp
Net margin24.6%+1.9pp
FCF margin24.4%+2.8pp

Returns & leverage

See full
Return on equity72.9%+13.6pp
Debt / equity0.4×-0.1×
Current ratio1.1×0.0×

Where this comes from

Reported directly by Idexx Laboratories in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Idexx Laboratories’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Idexx Laboratories's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Idexx Laboratories's cash & equivalents?
Idexx Laboratories (IDXX) reported cash & equivalents of $200.53M in Q1 2026.
How has Idexx Laboratories's cash & equivalents changed year-over-year?
Idexx Laboratories's cash & equivalents increased by 22.3% year-over-year, from $163.97M to $200.53M.
What is the long-term trend for Idexx Laboratories's cash & equivalents?
Over 5 years (2020 to 2025), Idexx Laboratories's cash & equivalents has grown at a -14.1% compound annual growth rate (CAGR), from $383.93M to $180.07M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.